keyboard_arrow_up

Head and Neck Cancer 2024 Market Forecast Analysis

ReportsnReports.com adds “Head and Neck Cancers - Epidemiology Forecast to 2024” to its store. The report provides an overview of the Head and Neck Cancer’s market outlook.

Epidemiologists forecast an increase in diagnosed incident cases of HNCs in the 7MM from 151,393 diagnosed incident cases in 2014 to 174,056 diagnosed incident cases in 2024, with an Annual Growth Rate (AGR) of 1.50% during the forecast period. In 2024, the US will have the highest number of diagnosed incident cases of HNCs in the 7MM, with 65,663 diagnosed incident cases, whereas the UK will have the lowest number of diagnosed incident cases of HNCs, with 12,702 diagnosed incident cases in 2024. The diagnosed incident cases of thyroid cancer in the 7MM are expected to increase from 93,225 diagnosed incident cases in 2014 to 123,504 diagnosed incident cases in 2024, with an AGR of 3.25% during the forecast period. In 2024, the US will have the highest number of diagnosed incident cases of thyroid cancer in the 7MM with 81,286 diagnosed incident cases, whereas Spain will have the lowest number of diagnosed incident cases of thyroid cancer with 3,233 diagnosed incident cases in 2024.

Request sample for this research at: http://www.reportsnreports.com/contacts/requestsample.aspx?name=496129 .

Scope for this research:

·         The Head and neck cancers (HNCs) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for HNCs in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the diagnosed incident cases of HNCs segmented into three sub-groups: cancers of the lip, oral cavity, and pharynx; cancers of the nose, sinuses, and related structures; and cancers of the larynx, in these markets. It also includes a 10-year epidemiological forecast for the five-year diagnosed prevalent cases of HNCs (excluding nose, sinuses, and related cancers). Additionally, it includes a 10-year epidemiological forecast for the diagnosed incident cases and the five-year diagnosed prevalent cases of thyroid cancer in the 7MM. The diagnosed incident cases of HNCs (excluding nose, sinuses, and related cancers) and thyroid cancer are segmented by age, sex, clinical stage at diagnosis, and histology.

·         The HNCs epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

·         The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy this Head and Neck Cancers research:

The HNCs EpiCast report will allow you to -

·         Develop business strategies by understanding the trends shaping and driving the global HNCs market.

·         Quantify patient populations in the global HNCs market to improve product design, pricing, and launch plans.

·         Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for HNCs therapeutics in each of the markets covered.